-
Latest News
- Elements of suffering in ME/CFS… in the severely & very severely affected
- The Chronic Illness Survey Adventure – an international study of symptoms
- Understanding the economic impact of ME/CFS in Ireland
- If you are living with ME – #YouAreNotAlone #MillionsMissing
- Blue Sunday Tea Party 16 May 2021 – raise awareness & funds
Archives
Tag Archives: Prof Olav Mella
Intravenous cyclophosphamide in ME/CFS. An open-label phase II study
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study by Ingrid G Rekeland, Alexander Fosså, Asgeir Lande, Irini Ktoridou-Valen, Kari Sørland, Mari Holsen, Karl J Tronstad, Kristin Risa, Kine Alme, Marte K Viken, Benedicte A Lie, Olav … Continue reading
Posted in News
Tagged Alexander Fosså, Asgeir Lande, Benedicte A Lie, cancer, chemotherapy, CycloME study, Cyclophosphamide, Ingrid G Rekeland, Irini Ktoridou-Valen, Kari Sorland, Karl J Tronstad, Kine Alme, Kristin Risa, Mari Holsen, Marte K Viken, Olav Dahl, Øystein Fluge, Prof Olav Mella
Comments Off on Intravenous cyclophosphamide in ME/CFS. An open-label phase II study
Human Leukocyte Antigen alleles associated with ME/CFS
Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), by Asgeir Lande, Øystein Fluge, Elin B Strand, Siri T Flåm, Daysi D Sosa, Olav Mella, Torstein Egeland, Ola D Saugsta, Benedicte A Lie, Marte K Viken in Scientific … Continue reading
Posted in News
Tagged autoimmune disorders, Benedicte A Lie, Daysi D Sosa, Dr Oystein Fluge, Elin B Strand, genes, genotypes, HLA genes, human leukocyte antigen molecules, Marte K Viken, Ola D Saugsta, Prof Olav Mella, Siri T Flåm, Torstein Egeland
Comments Off on Human Leukocyte Antigen alleles associated with ME/CFS
B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
B-lymphocyte depletion in patients With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: a randomized, double-blind, placebo-controlled trial by Oystein Fluge, Ingrid G. Rekeland, Katarina Lien, Hanne Thurmer, Petter C. Borchgrevink, Christoph Schafer, Kari Sorland, Jorg Assmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E. … Continue reading
Posted in News
Tagged B-lymphocyte depletion, Dr Oystein Fluge, Dr Peter Rowe, Prof Olav Mella, rituxan, rituximab
Comments Off on B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results
Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Oliver P Günther, Jennifer L Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R Miller, Shoshana M Parker, Stephen A Johnston, David M Patrick in Molecular Neurobiology (2018) pp 1-9 [Published online: … Continue reading
Posted in News
Tagged biomarker, diagnostic marker, Dr David Patrick, Dr Oystein Fluge, immune dysfunction, immunosignature, Jennifer L Gardy, Oliver P Günther, Patrick Tang, Phillip Stafford, Prof Olav Mella, Ruth R Miller, Shoshana M Parker, Stephen A Johnston
Comments Off on Immunosignature analysis of ME/CFS – promising diagnostic biomarker
Norwegian rituximab trial reports negative results
The Norwegian Rituximab trial reports negative results ahead of the publication of the full results. Attempts are now under way to determine the best way forward in understanding what has been learned and how to find out which patients may still benefit from … Continue reading
Posted in News
Tagged B-cell, Cort Johnson, Cyclophosphamide, Dr Oystein Fluge, Prof Olav Mella, rituximab, Simmaron Research
Comments Off on Norwegian rituximab trial reports negative results
Norwegian Rituximab studies update
Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading
Posted in News
Tagged antibodies, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, RituxME
Comments Off on Norwegian Rituximab studies update
New rituximab trial results from Norway
Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading
Posted in News
Tagged B-cell, Dr Oystein Fluge, Norway, Prof Olav Mella, rituximab, T-cell
Comments Off on New rituximab trial results from Norway
